`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`RANBAXY LABORATORIES LTD and RANBAXY INC.,
`Petitioners
`
`v.
`
`ADAMAS PHARMACEUTICALS, INC.,
`Patent Owner
`
`
`
`
`Inter Partes Review No.: 2015-00410
`
`U.S. Patent No. 8,362,085
`
`
`Petitioners’ Mandatory Notices – Updated Identification of Counsel
`37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Petitioners Ranbaxy Laboratories Ltd. and Ranbaxy Inc. (“Petitioners”) hereby
`
`provide notice that it has updated counsel in this proceeding. Petitioners have added
`
`John W. Bateman as lead counsel, and Karen C. Shen as back-up counsel. Pursuant
`
`to 37 C.F.R. § 42.8(a)(3), Petitioners’ updated mandatory notices are below, reflecting
`
`these amendments.
`
`I. MANDATORY NOTICES (37 C.F.R. § 42.8)
`A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))
`Ranbaxy Laboratories Limited and Ranbaxy Inc. are the real parties-in-interest
`
`for Petitioners.
`
`Ranbaxy Inc. is a wholly owned subsidiary of Ranbaxy Holdings (U.K.) Ltd.,
`
`which is a wholly owned subsidiary of Ranbaxy (Netherlands) B.V., which is a wholly
`
`owned subsidiary of Ranbaxy Laboratories Ltd. Ranbaxy Laboratories Ltd. is a
`
`publicly held entity. Its shares are listed on the Stock Exchanges in India, viz.
`
`National Stock Exchange and The Stock Exchange, Mumbai. Its Global Depository
`
`Shares are listed on the Luxembourg Stock Exchange. Daiichi Sankyo Company,
`
`Ltd., a publicly traded entity on the Stock Exchanges in Japan, owns approximately
`
`64% of the outstanding shares of Ranbaxy Laboratories Ltd.’s stock.
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2))
`Petitioners are not aware of any reexamination certificates or pending
`
`prosecution concerning the ’085 patent. Petitioners are parties to a pending litigation
`
`
`
`2
`
`
`
`regarding infringement and invalidity of the ’085 patent, namely Forest Laboratories,
`
`Inc. et al v. Ranbaxy Inc. et. al, Civ. Action No. 14-cv-686, currently pending in the
`
`District of Delaware. There are also pending litigations regarding infringement and
`
`invalidity of the ’085 patent currently pending against additional parties in the District
`
`of Delaware, including Civ. Action Nos. 14-cv-121 , 14-cv-200, 14-cv-508, 14-cv-
`
`1058, and 14-cv-1271.
`
`There are also two pending applications claiming benefit to the ’085 patent,
`
`namely No. 14/081,643, filed on November 15, 2013, and No. 14/339,599, filed on
`
`July 24, 2014.
`
`C.
`
`Identification of Counsel (37 C.F.R. § 42.8(b)(3))
`
`Lead Counsel
`John W. Bateman
` (Reg. No. 41,602)
`KENYON & KENYON LLP
`1500 K Street, NW
`Washington, DC 20005
`jbateman@kenyon.com
`Tel: 202.220.4216
`Fax: 202.220.4201
`
`
`Back-up Counsel
`Karen C. Shen
` (Reg. No. 60,412)
`KENYON & KENYON LLP
`One Broadway
`New York, NY 10004-1007
`kshen@kenyon.com
`Tel: 212.908.6206
`Fax: 212.425.5288
`
`D.
`Service Information (37 C.F.R. § 42.8(b)(4))
`Please direct all correspondence to lead counsel and back-up counsel at the
`
`contact information above. Petitioners consent to service by electronic mail at
`
`jbateman@kenyon.com and kshen@kenyon.com.
`
`
`
`3
`
`
`
`
`Dated: February 20, 2015
`
`
`
`John W. Bateman
` (Reg. No. 41,602)
`KENYON & KENYON LLP
`1500 K Street, NW
`Washington, DC 20005
`jbateman@kenyon.com
`Tel: 202.220.4216
`Fax: 202.220.4201
`
`
`
`
`
`
`
`4
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby confirms that the foregoing Petitzbnerr’Marzdatog;
`
`Native: — Updated Identification of Camera] was served on February 20, 2015 Via e—email
`
`upon the following counsel of record for the Patent Owner.
`
`Peter]. Armenio, PC.
`
`QUINN EL-mmNUEL URQUHART 8: SULLIVAN, LLP
`
`51 Madison Avenue
`
`2211d Floor
`
`New York, NY 10010
`
`Evangeline L. Shih
`
`QUINN EMMANUEL URQUHAR’1‘& SULLIVAN, LLP
`
`51 Madison Avenue
`
`22'“1 Floor
`
`New York, NY 10010
`
` Dated: February 20, 2015
`
` Hannah Rose Stein
`
`KENYON & KENYON LLP
`
`One Broadway
`New York, NY 10004—1007
`hstcin@kenyon.com
`Tel: 212.908.6398
`
`Fax: 212.425.5288
`
`